Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT01499394
Recruiting Observational

Caris Biorepository Research Protocol

NCT01499394 · tracked via the Priya Life Science USA tracker
Sponsor
Caris Science, Inc
Phase
Observational
Started
2010-11
Last updated
2026-01-21

Condition(s) studied

CancerEarly Detection of CancerMinimal Residual Disease

Study summary

The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients.

The Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * 18 years of age or older * Capacity to provide informed consent Exclusion Criteria: * Due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoners-patients will not be approached for participation in the Caris Biorepository. * Minor subjects will not be included in the Caris Biorepository, as it is possible biospecimens and data may be stored beyond the time limitations of assent and it may be impracticable to re-consent these subjects once they become adults. * Individuals who lack the capacity to give informed consent

Primary outcome measure(s)

  • Develop biorepository that ensures molecular integrity and clinical relevance of quality human biospecimens and associated clinical data. — 35 years
    Retention of biospecimen samples with DNA
  • Implement release of specimens from biorepository for testing — 35 years
    Research for the purposes of cancer laboratory diagnostic tests.

Trial sites (38)

FacilityCityRegionStatus
University of South Alabama Mobile Alabama Recruiting
Southwest Medical Imaging Scottsdale Arizona Recruiting
St. Bernards Medical Center Jonesboro Arkansas Recruiting
CARTI Cancer Center Little Rock Arkansas Recruiting
ObjectiveHealth - ARcare Center for Clinical Research Little Rock Arkansas Recruiting
Lee Memorial Health System Fort Myers Florida Recruiting
Cancer Care of North Florida Lake City Florida Recruiting
Advent Health Orlando Florida Recruiting
The University of South Florida Tampa Florida Recruiting
Cleveland Clinic Florida Weston Florida Recruiting
Phoebe Putney Memorial Hospital Albany Georgia Recruiting
Emory University Atlanta Georgia Recruiting
Augusta University Research Institute Augusta Georgia Recruiting
Cancer Center of Middle Georgia Dublin Georgia Recruiting
Hope and Healing Cancer Services Hinsdale Illinois Recruiting
CHRISTUS - St. Frances Cabrini Hospital Alexandria Louisiana Recruiting
Tulane University New Orleans Louisiana Recruiting
CHRISTUS - Highland Medical Center Shreveport Louisiana Recruiting
Mercy Medical Center Baltimore Maryland Recruiting
Sinai Hospital of Baltimore Baltimore Maryland Recruiting
Hattiesburg Clinic Hattiesburg Mississippi Recruiting
Jackson Oncology Associates Jackson Mississippi Recruiting
University of Mississippi Medical Center Jackson Mississippi Recruiting
ObjectiveHealth - Premier Health Research Sparta New Jersey Recruiting
CHRISTUS - St. Vincent Regional Cancer Center Santa Fe New Mexico Recruiting
St. Lawrence Health System Potsdam New York Recruiting
National Translational Research Group Ridge New York Recruiting
Altru Health System Grand Forks North Dakota Recruiting
NEO Urology Associates Boardman Ohio Recruiting
Great Lakes Medical Research Cleveland Ohio Recruiting
Bend Memorial Clinic Bend Oregon Recruiting
Clinical Biotechnology Research Institute at RSFH Charleston South Carolina Recruiting
Spartanburg Regional Health Services Spartanburg South Carolina Recruiting
West Cancer Center Germantown Tennessee Recruiting
ObjectiveHealth - Amarillo Premier Research Amarillo Texas Recruiting
CHRISTUS - St. Michael's Health Texarkana Texas Recruiting
CAMC Clinical Trials Charleston West Virginia Recruiting
Mercy Health Janesville Wisconsin Recruiting

More Caris Science, Inc. trials in the USA

Caris Chromoseq Data Collection Recruiting

Other trials for the same condition

An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare. Recruiting
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors Recruiting
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Enrolling by invitation
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors Recruiting
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01499394 on ClinicalTrials.gov ↗ ← All trials in the USA